ARVN

Arvinas, Inc. (NASDAQ:ARVN) is a clinical-stage biopharmaceutical company founded in 2013 and headquartered in New Haven, Connecticut. The company pioneered the development of <b>PROTAC (Proteolysis Targeting Chimera)</b> protein degradation technology, a novel therapeutic approach that selectively degrades disease-causing proteins rather than simply inhibiting them. Since going public in 2018, Arvinas has advanced multiple drug candidates through clinical trials, with its lead breast cancer treatment <b>vepdegestrant</b> showing promising Phase 3 results in early 2025. The company has established strategic partnerships with major pharmaceutical companies including Pfizer, Genentech, Novartis, and Bayer to advance its innovative protein degradation platform.